Sustained R&D Investment
10–20% of annual revenue reinvested
For Genrui, R&D is a long-term commitment, not a discretionary cost. Each year the company reinvests about 10–20% of its annual revenue into research and development, funding the science, engineering and validation behind every solution we bring to market.
A Highly Qualified Engineering Team
Over 70% hold a master's degree or higher
More than 70% of Genrui's R&D engineers hold a master's degree or higher, trained in immunology, biochemistry, electronics and software. Their depth of expertise is what turns complex science into instruments and reagents laboratories can rely on every day.
A Growing Patent Portfolio
200+ patent applications filed
Genrui has filed more than 200 patent applications covering core technologies across its instrument and reagent platforms — from optical detection and fluidics to immunoassay methods and reagent formulations. Each reflects original engineering that partners can build on with confidence.
New Products Every Year
3–8 new products launched annually
Genrui launches 3 to 8 new products annually, spanning both analyzers and reagents across hematology, specific protein, POCT, chemiluminescence and clinical chemistry.
